Diabetes Prevention Program Outcomes Study (DPPOS) Continuation

May 2020 Council

Lead Division/Office


Point(s) of Contact

Barbara Linder, M.D., Ph.D.

Executive Summary

The Diabetes Prevention Program Outcomes Study (DPPOS) is the longitudinal follow-up of the cohort that participated in the Diabetes Prevention Program (DPP) trial, which established the efficacy of intensive lifestyle modification or metformin in decreasing incidence of type 2 diabetes in individuals at high risk for developing the disease. The DPP results led to the creation of the National DPP, which is covered by many private insurers and Medicare.

At the end of DPP, participants were offered a modified lifestyle intervention and the metformin group was offered continued open label treatment with metformin. Since 2002, participants have been followed in DPPOS to assess the longer-term effects of the original DPP interventions on multiple outcomes, and to document the clinical course of incident diabetes in the modern treatment era. The study also provides the opportunity to study aging-associated co-morbidities, including cognition, physical functioning/frailty, and multi-morbidity. The current phase is also examining if metformin decreases incident cancer and/or CVD. Funding for DPPOS will end in January 2022; the investigators are developing a proposal for continued follow-up of the cohort. An External Evaluation Panel will be convened over the summer of 2020 to provide input to NIH about the scientific importance of the proposal, to assist NIDDK and the collaborating co-funders in determining whether to accept a competitive renewal application or close-out the study.